These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33206021)

  • 1. A health economic guide to market access of biosimilars.
    Simoens S; Vulto AG
    Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
    [No Abstract]   [Full Text] [Related]  

  • 2. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
    Pentek M; Zrubka Z; Gulacsi L
    Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: A Value Proposition.
    de Mora F
    BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of biosimilars.
    Blackstone EA; Joseph PF
    Am Health Drug Benefits; 2013 Sep; 6(8):469-78. PubMed ID: 24991376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
    Río-Álvarez I; Cruz-Martos E
    Expert Opin Biol Ther; 2024 Jul; 24(7):583-597. PubMed ID: 38842367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short and long-term economic implications of biosimilars.
    Al Meslamani AZ
    Expert Opin Biol Ther; 2024 Jul; 24(7):567-570. PubMed ID: 38231118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stakeholder perspectives on the sustainability of the United States biosimilars market.
    Sullivan SD; Humphreys SZ; Fox D; Lockhart CM; Tait-Dinger A; Betancourt JD; Komorny KM; Haumschild R; Chester B; Harman M; Roth JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1065-1072. PubMed ID: 39012302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
    Böhm AK; Steiner IM; Stargardt T
    Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Kim H; Alten R; Avedano L; Dignass A; Gomollón F; Greveson K; Halfvarson J; Irving PM; Jahnsen J; Lakatos PL; Lee J; Makri S; Parker B; Peyrin-Biroulet L; Schreiber S; Simoens S; Westhovens R; Danese S; Jeong JH
    Drugs; 2020 Feb; 80(2):99-113. PubMed ID: 32002851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
    Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report.
    Barcina Lacosta T; Inotai A; Pereira CL; Barbier L; Simoens S
    Value Health; 2024 May; 27(5):543-551. PubMed ID: 38702140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.